By Dr. Chinta SidharthanOct 30 2023Reviewed by Lily Ramsey, LLM In a recent study published in The Lancet Respiratory Medicine, a team of researchers from the United States examined the efficacy of the bivalent Pfizer-BioNTech coronavirus disease 2019 messenger ribonucleic acid vaccine BNT162b2 BA.4/5 in preventing severe acute respiratory syndrome coronavirus 2 XBB lineage infections.
The Omicron variant and its sub-lineages have been known to carry numerous novel mutations. Although Omicron infections are less virulent, the transmissibility of this lineage has been high due to its immune evasive abilities. Related StoriesThe case-control study was designed on a test-negative basis and examined the effectiveness of the bivalent BNT162b2 BA.4/BA.5 vaccine in protecting against various COVID-19 outcomes, such as hospital admission, outpatient visits, emergency department visits, and critical illness requiring access in the intensive care unit , the need for mechanical ventilation, or mortality.
The examined outcomes included the odds of vaccination between COVID-19-positive cases and test-negative controls.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.